



# Ilumya in India

*The CDSCO named-patient coordination pathway — indicative 2026*

IMMUNOLOGY · MODERATE-TO-SEVERE PLAQUE PSORIASIS

## The clinical situation

Ilumya (tildrakizumab-asmn) is a subcutaneous anti-IL-23 (p19) monoclonal antibody FDA-approved for moderate-to-severe plaque psoriasis in adult candidates for systemic therapy or phototherapy. Manufactured by Sun Pharma. Dosing is 100 mg SC at weeks 0 and 4, then every 12 weeks thereafter. Pre-treatment workup covers TB screening, hepatitis B/C serology, vaccination status, and baseline infection review per FDA labelling.

### The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your dermatologist documents plaque-psoriasis severity (BSA, PASI, DLQI), prior systemics, and Ilumya rationale.
- 2 Baseline screening.** TB, hepatitis B/C, vaccinations, and infection review completed per FDA labelling.
- 3 CDSCO named-patient application.** Physician or hospital pharmacy files clinical rationale, patient reference, dosing calendar, and chain-of-custody commitment.
- 4 US-side sourcing & cold-chain logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner with validated 2–8°C shipment.
- 5 Arrival & first dose.** Dispensing pharmacy releases product against the prescription; your dermatologist administers the first dose with ongoing IL-23-class monitoring.

### Indicative economics

**Reference US cash-pay range:** USD 16,000–19,000 per quarterly Ilumya maintenance dose (drug-only reference; Reserve Meds provides a transparent delivered quote at intake).

### Indicative first-dose timing

**7–14 days** from a complete CDSCO application to first dispensation, once cohort intake opens. Indicative — not guaranteed.

## Reserve Meds's role

**Sourcing.** US-licensed specialty wholesale partner, DSCSA chain-of-custody from Sun Pharma authorised distribution.

**Documentation.** Physician kit tailored to CDSCO review, with IL-23 class safety annex. **Logistics.** Validated cold-chain

internationally tracked shipment. **Concierge case lead.** Named point of contact for family and physician through each quarterly cycle. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating physician.

**COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST**

**Join the Ilumya × India first-cohort waitlist.** *Our concierge reaches out as we open intake.*

[reservemed.com/access-guides/ilumya-india.html](https://reservemed.com/access-guides/ilumya-india.html)



SCAN TO JOIN

**Reserve Meds** · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

*Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.*

**reservemed.com** · [hello@reservemed.com](mailto:hello@reservemed.com) · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team